Citius Pharmaceuticals, Inc.
CTXR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001506251
No open-market purchases or sales by Citius Pharmaceuticals, Inc. insiders were filed in the last 90 days; 42 institutions reported holding it in 13F filings for Q2 2026, worth $822.4K in total; no superinvestor holds it.
Q2 2025 vs. Q1 2025
How the institutions holding Citius Pharmaceuticals, Inc. changed between Q1 2025 and Q2 2025.
All holders in Q2 2025All holders in Q1 2025
| Measure | Q1 2025 | Q2 2025 | Change |
|---|---|---|---|
| Holders | 28 | 31 | +3 |
| Shares | 635.5K | 928.8K | +293.3K (+46.1%) |
| Value | $947.2K | $1.48M | +$529.9K (+55.9%) |
New holders (8)
Institutions that held Citius Pharmaceuticals, Inc. at the end of Q2 2025 but not at the end of Q1 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Cambridge Investment Research Advisors, Inc. | 183,534 | $292.0K | 0.00% |
| Heights Capital Management, Inc | 159,898 | $254.2K | 0.08% |
| GWM Advisors LLC | 25,000 | $39.8K | 0.00% |
| XTX Topco Ltd | 20,146 | $32.0K | 0.00% |
| Susquehanna International Group, LLP | 14,199 | $22.6K | 0.00% |
| Two Sigma Investments, LP | 12,874 | $20.5K | 0.00% |
| Raymond James Financial Inc | 226 | $359 | 0.00% |
| Larson Financial Group LLC | 45 | $72 | 0.00% |
Sold out (5)
Institutions that held Citius Pharmaceuticals, Inc. at the end of Q1 2025 and filed for Q2 2025 without it.
| Institution | Shares, Q1 2025 | Value, Q1 2025 |
|---|---|---|
| Squarepoint Ops LLC | 60,983 | $90.9K |
| Tower Research Capital LLC (TRC) | 4,410 | $6.57K |
| Simplex Trading, LLC | 966 | $1.00K |
| Quent Capital, LLC | 108 | $161 |
| Barclays PLC | 29 | $43 |